Venture Capital To Indian Biotechs Lagging This Year
This article was originally published in PharmAsia News
Executive Summary
Venture capital investments in Indian biotechs have dropped, according to a report on the first quarter of this year. Dow Jones VentureSources counted $11 million invested in only two biopharmaceutical deals during that three-month period. Last year, $99.5 million was invested in life sciences and health care companies in India. An official at MPM Capital, which with TPG Ventures, was among early investors in early-stage biotechs in India, says he still expects the number of life sciences deals to grow. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.